Loading...

Urinary Angiotensinogen Could Be a Prognostic Marker of the Renoprotection of Olmesartan in Metabolic Syndrome Patients

This study was performed to demonstrate urinary angiotensinogen as a potential prognostic marker of the albuminuria reduction effects of olmesartan in patients with metabolic syndrome. In 24 patients (eight women, 57.88 ± 2.00 years), 5–40 mg/day of olmesartan were given. Urinary concentrations of a...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Int J Mol Sci
Main Authors: Mizushige, Tomoko, Kobori, Hiroyuki, Hitomi, Hirofumi, Nishijima, Yoko, Tomoda, Fumihiro, Morimoto, Satoshi, Kohno, Masakazu, Nishiyama, Akira
Format: Artigo
Sprog:Inglês
Udgivet: MDPI 2016
Fag:
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5133801/
https://ncbi.nlm.nih.gov/pubmed/27801805
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ijms17111800
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!